Three recently published studies by Medical University of South Carolina researchers each adopted a unique approach to ...

Because it causes tissue damage and tissue death in the legs, feet, and toes, PAD is implicated in 150,000 lower-limb ...

Caribou plans a pivotal Phase 3 randomized trial evaluating approximately 250 patients in second-line large B-cell lymphoma. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Orphan ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Memorial Sloan Kettering Cancer Center researchers continued to make strides against cancer in 2025. Learn about some of ...

The billionaire-backed “Doping Games” is luring Olympian-caliber athletes with cash, drugs, and science. Are these athletes ...

An in-depth look at how Turkey’s top clinics use next-generation technology to deliver superior results at globally ...

IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 12:30 PM ESTCompany ParticipantsShaun Bagai - ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for ...

Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.

The ASX healthcare sector has logged another week in the red and, without a Christmas miracle, looks set to end 2025 as the ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ...